Suppr超能文献

比较不同内分泌治疗方案治疗早期乳腺癌的绝经前妇女血脂谱的变化。

Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies.

机构信息

Department of Breast Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China.

Cancer Institute (The Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), Department of Surgical Oncology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China.

出版信息

Sci Rep. 2022 Dec 31;12(1):22650. doi: 10.1038/s41598-022-27008-x.

Abstract

Adjuvant endocrine therapy improves the prognosis of early breast cancer with hormone receptor positivity. However, there is no systematic report on the effect of endocrine therapy (particularly ovarian function suppression, OFS) on serum lipids in premenopausal women. This retrospective cohort study aimed to determine whether various endocrine treatments had different effects on blood lipids. This study enrolled 160 premenopausal patients with stage I-III breast cancer in eastern China. The initial diagnostic information was retrieved from patient's medical records, including age at the time of diagnosis, tumor characteristics, anticancer treatment and past medical history. The changes in blood lipids in patients receiving different types of endocrine therapy were compared at the 3rd, 6th, 12th, and 24th months after initiating endocrine therapy. Generalized linear mixed model was used in our analyses. Our data revealed that low-density lipoprotein cholesterol (LDL-C) levels in patients with tamoxifen (TAM) were significantly lower in the 6th, 12th, and 24th months than that in the 3rd month, while high-density lipoprotein cholesterol (HDL-C) levels in the 6th, 12th, and 24th months were significantly higher than that in the 3rd month, indicating that blood lipid levels generally improved with time. While in TAM plus OFS group, HDL-C levels were significantly higher in the 24th month than in the 3rd month, total cholesterol (TC) levels were significantly higher in the 24th month than in the 6th month. The lipid profiles of OFS plus aromatase inhibitor (AI) group did not show significant differences at any time point but were significantly higher than those of the other two groups especially in LDL and TC. TAM group tended to have lower serum lipid levels. With longer follow-up, no statistically significant difference in values was observed between TAM and TAM plus OFS groups at various time points. Compared with the other two groups, OFS plus AI group presented an increasing trend toward LDL-C and TC. The risk of dyslipidemia requires further investigation using a large sample size.

摘要

辅助内分泌治疗改善了激素受体阳性的早期乳腺癌患者的预后。然而,目前尚无系统的关于绝经前妇女内分泌治疗(尤其是卵巢功能抑制)对血脂影响的报告。本回顾性队列研究旨在确定各种内分泌治疗对血脂的影响是否不同。本研究纳入了中国东部地区 160 例 I-III 期乳腺癌的绝经前患者。初始诊断信息从患者的病历中获取,包括诊断时的年龄、肿瘤特征、抗癌治疗和既往病史。在开始内分泌治疗后的第 3、6、12 和 24 个月,比较了接受不同类型内分泌治疗的患者的血脂变化。我们的分析使用了广义线性混合模型。我们的数据显示,与第 3 个月相比,接受他莫昔芬(TAM)治疗的患者的低密度脂蛋白胆固醇(LDL-C)水平在第 6、12 和 24 个月显著降低,而高密度脂蛋白胆固醇(HDL-C)水平在第 6、12 和 24 个月显著升高,表明随着时间的推移,血脂水平普遍改善。而在 TAM 加卵巢功能抑制(OFS)组中,第 24 个月的 HDL-C 水平显著高于第 3 个月,第 24 个月的总胆固醇(TC)水平显著高于第 6 个月。OFS 加芳香化酶抑制剂(AI)组的血脂谱在任何时间点均无显著差异,但均明显高于其他两组,尤其是 LDL 和 TC。TAM 组的血清血脂水平较低。随着随访时间的延长,在各个时间点,TAM 组和 TAM 加 OFS 组之间的数值没有统计学差异。与其他两组相比,OFS 加 AI 组的 LDL-C 和 TC 呈升高趋势。血脂异常的风险需要进一步用大样本量进行调查。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4918/9805421/d7b64c7f0dad/41598_2022_27008_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验